Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2020
>
FDA Authorizes Marketing of the First Genetic Test to Aid in the Diagnosis of Fragile X Syndrome
FDA Authorizes Marketing of the First Genetic Test to Aid in the Diagnosis of Fragile X Syndrome
Read also
FDA Clears Gain Therapeutics to Launch Global Parkinson's Phase 2 Trial
Gain Therapeutics received FDA IND clearance to launch a multi-continent Phase 2 clinical trial of GT-02287, an oral small molecule for Parkinson's.
MIRA Pharmaceuticals Reports Promising SKNY-1 Data for Obesity Tracking
MIRA Pharmaceuticals shared new preclinical data for SKNY-1, an oral candidate demonstrating strong brain penetration and once-daily dosing potential.
UCLA Wins $7.49M CIRM Grant to Advance Novel Multiple Sclerosis Therapy
A UCLA research team led by Dr. Lili Yang secured a $7.49M CIRM grant to transition an engineered NKT cell-based immunotherapy for MS into clinical trials.
Breakthrough HIV Vaccine Candidate Shows Major Promise in Primate Study
An experimental HIV vaccine from LJI and Scripps Research successfully generated broadly neutralizing antibodies in primates, marking a historic milestone.
